[1] KOVESDI I, REICHEL R, NEVINS J R. Identification of a cellular transcription factor involved in E1A trans-activation[J]. Cell, 1986, 45(2): 219-228.
[2] KASSAB A, GUPTA I, MOUSTAFA A A. Role of E2F transcription factor in oral cancer: recent insight and advancements[J]. Semin Cancer Biol, 2023, 92: 28-41.
[3] HSU J, SAGE J. Novel functions for the transcription factor E2F4 in development and disease[J]. Cell Cycle, 2016, 15(23): 3183-3190.
[4] ALTINOZ M A, TUNAL- N E. Trinucleotide repeat expansions in human breast cancer-susceptibility genes: relevant targets for aspirin chemoprevention?[J]. Clin Transl Oncol, 2016, 18(1): 9-17.
[5] BEIJERSBERGEN R L, KERKHOVEN R M, ZHU L, et al. E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo[J]. Genes Dev, 1994, 8(22): 2680-2690.
[6] GINSBERG D, VAIRO G, CHITTENDEN T, et al. E2F-4, a new member of the E2F transcription factor family, interacts with p107[J]. Genes Dev, 1994, 8(22): 2665-2679.
[7] WANG Z X. Regulation of cell cycle progression by growth factor-induced cell signaling[J]. Cells, 2021, 10(12): 3327.
[8] PERSENGIEV S P, KONDOVA I I, KILPATRICK D L. E2F4 actively promotes the initiation and maintenance of nerve growth factor-induced cell differentiation[J]. Mol Cell Biol, 1999, 19(9): 6048-6056.
[9] KIM S, MA L N, SHOKHIREV M N, et al. Multicilin and activated E2f4 induce multiciliated cell differentiation in primary fibroblasts[J]. Sci Rep, 2018, 8(1): 12369.
[10] ZHANG X W, XUE M, LIU A R, et al. Activation of Wnt/β-Catenin-p130/E2F4 promotes the differentiation of bone marrow-derived mesenchymal stem cells into type II alveolar epithelial cells through cell cycle arrest[J]. Exp Ther Med, 2023, 26(1): 330.
[11] LIU J Y, XIA L L, WANG S L, et al. E2F4 promotes the proliferation of hepatocellular carcinoma cells through upregulation of CDCA3[J]. J Cancer, 2021, 12(17): 5173-5180.
[12] XIAO W J, WANG J Q, WANG X J, et al. Therapeutic targeting of the USP2-E2F4 axis inhibits autophagic machinery essential for zinc homeostasis in cancer progression[J]. Autophagy, 2022, 18(11): 2615-2635.
[13] PARK S A, KIM L K, KIM Y T, et al. Long noncoding RNA E2F4as promotes progression and predicts patient prognosis in human ovarian cancer[J]. Cancers, 2020, 12(12): 3626.
[14] 张曦文. Wnt/β-Catenin-p130/E2F4调控细胞周期影响MSC向II型肺泡上皮细胞分化的机制及其在ARDS中的意义[D]. 南京: 东南大学, 2019.
[15] KENT L N, LEONE G. The broken cycle: E2F dysfunction incancer[J]. Nat Rev Cancer, 2019, 19: 326-338.
[16] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[17] WANG S A, WANG Y C, CHUANG Y P, et al. EGF-mediated inhibition of ubiquitin-specific peptidase 24 expression has a crucial role in tumorigenesis[J]. Oncogene, 2017, 36(21): 2930-2945.
[18] DRAGOJ M, BANKOVIC J, PODOLSKI-RENIC A, et al. Association of overexpressed MYC gene with altered PHACTR3 and E2F4 genes contributes to non-small cell lung carcinoma pathogenesis[J]. J Med Biochem, 2019, 38(2): 188-195.
[19] BANKOVIC J, STOJSIC J, JOVANOVIC D, et al. Identification of genes associated with non-small-cell lung cancer promotion and progression[J]. Lung Cancer, 2010, 67(2): 151-159.
[20] HO G H, CALVANO J E, BISOGNA M, et al. Expression of E2F-1 and E2F-4 is reduced in primary and metastatic breast carcinomas[J]. Breast Cancer Res Treat, 2001, 69(2): 115-122.
[21] MA X W, FAN M W, YANG K B, et al. ZNF500 abolishes breast cancer proliferation and sensitizes chemotherapy by stabilizing P53 via competing with MDM2[J]. Cancer Sci, 2023, 114(11): 4237-4251.
[22] YE G L, HE S Q, PAN R L, et al. circ_0041732 promotes breast cancer progression[J]. Mol Cancer Res, 2022, 20(10): 1561-1573.
[23] LIU Z L, BI X W, LIU P P, et al. Expressions and prognostic values of the E2F transcription factors in human breast carcinoma[J]. Cancer Manag Res, 2018, 10: 3521-3532.
[24] FARMAN F U, HAQ F, MUHAMMAD N, et al. Aberrant promoter methylation status is associated with upregulation of the E2F4 gene in breast cancer[J]. Oncol Lett, 2018, 15(6): 8461-8469.
[25] TOOLABI N, DALIRI F S, MOKHLESI A, et al. Identification of key regulators associated with colon cancer prognosis and pathogenesis[J]. J Cell Commun Signal, 2022, 16(1): 115-127.
[26] GARNEAU H, PAQUIN M C, CARRIER J C, et al. E2F4 expression is required for cell cycle progression of normal intestinal crypt cells and colorectal cancer cells[J]. J Cell Physiol, 2009, 221(2): 350-358.
[27] GUO Z, LIU X Z, SHAO H J. E2F4-induced AGAP2-AS1 up-regulation accelerates the progression of colorectal cancer via miR-182-5p/CFL1 axis[J]. Dig Liver Dis, 2022, 54(7): 878-889.
[28] YAO H B, LU F, SHAO Y F. The E2F family as potential biomarkers and therapeutic targets in colon cancer[J]. PeerJ, 2020, 8: e8562.
[29] BARAL S, YU Y T, SUN Q N, et al. Transcription factor E2F4 promote proliferation, migration, and invasion of gastric cancer cells by transcriptionally activating DSCC1[J]. Int J Biol Sci, 2024, 20(12): 4978-4998.
[30] WANG Y, SUN B, WEI W, et al. NUCB2 promotes hepatocellular carcinoma cell growth and metastasis by activating the E2F4/PTGR1 axis[J]. Int J Biol Sci, 2024, 20(12): 4767-4780.
[31] MA Z W, LI Q L, WANG W J, et al. Transcription factor E2F4 facilitates SUMOylation to promote HCC progression through interaction with LIN9[J]. Int J Oncol, 2024, 65(4): 98.
[32] LU Z, LUO R Z, PENG H Q, et al. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer[J]. Clin Cancer Res, 2006, 12(8): 2404-2413.
[33] KIM J, YIM G W, LEE D W, et al. Knockdown of E2F4 suppresses the growth of ovarian cancer cells through the cell cycle pathway[J]. Int J Clin Exp Pathol, 2021, 14(8): 866-874.
[34] WANG M, GUO C, WANG L, et al. Long noncoding RNA GAS5 promotes bladder cancer cells apoptosis through inhibiting EZH2 transcription[J]. Cell Death Dis, 2018, 9(2): 238.
[35] YANG H Y, QU X L, HUANG J G, et al. E2F4 may be a core transcription factor in the lncRNA-TF regulatory network in cervical cancer[J]. J Clin Lab Anal, 2022, 36(4): e24322.
[36] ZHENG Y C, FEI H. High expression of E2F4 is an adverse prognostic factor and related to immune infiltration in oral squamous cell carcinoma[J]. Biomed Res Int, 2022, 2022: 4731364.
[37] CHEN R, ZHANG Z C, HU B, et al. Identification of the expression and clinical significance of E2F family in clear cell renal cell carcinoma[J]. Int J Gen Med, 2022, 15: 1193-1212. |
